Bad Berka Heart Rhythm Registry for people with or at risk of heart rhythm problems treated at Heart Center Bad Berka
Official title: The Bad Berka Heart Rhythm Registry (2B2R) is a Prospective, Single-center Observational Cohort Evaluating Safety, Efficacy, and Outcomes in Patients Undergoing Arrhythmia Therapy or CIED Implantation at the Heart Center Bad Berka
Run by Zentralklinik Bad Berka · NCT07020910 · Data updated 2026-11-12
This registry will collect information from adults with or at risk of heart rhythm problems treated at the Heart Center Bad Berka to see which treatments, devices, and technologies work best and are safest.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Zentralklinik Bad Berka Academic / other |
| Locations | 1 site (Bad Berka) |
| Status | Recruiting |
| Started | August 1, 2024 |
| Main results expected | August 1, 2029 |
| Study ends | August 1, 2034 |
| Registry record updated | September 9, 2026 |
| Trial ID | NCT07020910 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18 and older) with documented or suspected cardiac arrhythmias who are receiving medical or interventional therapy or device implantation at Heart Center Bad Berka and can give informed consent are eligible.
✕Probably not a fit
Patients who cannot provide informed consent, who are enrolled in an incompatible interventional trial, or who are treated outside the center are unlikely to derive direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Bad Berka Heart Rhythm Registry is a prospective, single-center observational cohort that will systematically collect clinical, procedural, imaging, device, and patient-reported data from adults treated for cardiac arrhythmias at Heart Center Bad Berka. Data collected will include procedural parameters, acute success, complication rates, device therapy details, and standardized follow-up outcomes, with planned substudies on technologies such as pulsed field ablation, high-density mapping, and conduction system or device-based therapies. The registry will capture patients undergoing medical therapy, electrophysiology studies, catheter ablation, interventional stroke-prevention, and cardiac electronic device implantation. Analyses will seek predictors of outcomes and complications, compare procedural strategies, and generate real-world evidence to support clinical decision-making and quality assurance.
Why it matters
Potential benefit: If successful, the registry could help clinicians choose safer and more effective arrhythmia treatments and device strategies by providing real-world outcome data.
How similar studies have gone: Other large electrophysiology registries have provided valuable real-world safety and effectiveness data, though approaches like pulsed field ablation and conduction system pacing remain relatively newer and less extensively characterized in registries.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * At risk of or with documented cardiac arrhythmia undergoing medical or interventional therapy at the Heart Center Bad Berka * Informed consent obtained Exclusion Criteria: * Inability or unwillingness to provide informed consent * Participation in another interventional trial that precludes registry inclusion
Where it's running
-
Zentralklinik Bad Berka
Bad Berka, Germany Recruiting
Study contacts
- Study coordinator: Christoph Geller, Prof. Dr. med.
- Email: kar@zentralklinik.de
- Phone: +49 (0) 36458 5-1201 / 1205
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predict Arrhythmia Risk with Intelligent Software
Researchers are testing AI-powered predictions to see if clinicians can spot patients at risk for dangerous heart rhythms using bedside ECG data.
-
Rhythm control for device-detected AHREs in adults with no prior AF
This trial tests whether starting rhythm-control therapy plus risk-factor management helps people with device-detected AHREs lasting 6 minutes to 24 hours avoid progressing to clinical atrial fibrillation.
-
Gene testing for diagnosing and treating heart disease
This study is trying to see if gene testing can help doctors better diagnose and treat heart conditions related to arrhythmias in patients at the Cardiogenetic Center in Italy.
-
Evaluating a new cardiac imaging system for arrhythmias
This study is testing a new heart imaging system to see if it helps patients with arrhythmias during certain heart procedures.
-
AI analysis of ECGs for high-risk cardiac patients
This study is testing an AI tool that analyzes heart rhythm patterns in high-risk heart patients to see if it can help doctors catch problems earlier and improve patient care.
-
Observing heart rhythms in patients treated with BTK inhibitors or venetoclax
This study is testing how Bruton’s tyrosine kinase inhibitors affect heart rhythms in people with chronic lymphocytic leukemia and comparing it to those taking venetoclax to see if there are any risks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.